Form 4: Amgen Director Charles M. Holley Boosts Stake Through Equity Grant

Amgen Inc. Director Charles M. Holley has increased his direct beneficial ownership of company common stock by 809 shares through a Restricted Stock Unit grant and Dividend Equivalents, effective May 23, 2025.

Summary

• Charles M. Holley, a Director at Amgen Inc. (AMGN), acquired 809 shares of common stock on May 23, 2025.
• The acquisition was made at a price of $0 per share, indicating it was a grant or award.
• These shares were granted as Restricted Stock Units (RSUs) pursuant to the Amgen Inc. 2009 Director Incentive Program, which vested immediately.
• The acquired shares include 1,209 Dividend Equivalents (DEs) also granted under the Director Program and subject to a dividend reinvestment plan.
• Following this transaction, Mr. Holley directly beneficially owns 11,237.1742 shares of Amgen common stock.
• Additionally, Mr. Holley indirectly beneficially owns 1,260 shares through the Holley Family Trust.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through a grant, is generally a positive signal as it increases insider ownership and aligns interests with shareholders, indicating confidence in the company's long-term prospects.

Positives

• The acquisition of 809 shares by a director, even through a grant, increases insider ownership and aligns management interests with shareholders.
• The immediate vesting of the Restricted Stock Units (RSUs) provides the director with immediate ownership of the shares.
• The inclusion of Dividend Equivalents (DEs) indicates a mechanism for directors to benefit from dividends on their deferred equity, further aligning interests.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This insider transaction is a routine disclosure for a publicly traded biotechnology company like Amgen, reflecting compensation practices for its directors. It does not directly indicate broader industry trends but is a common mechanism for aligning director incentives with shareholder value in the pharmaceutical and biotech sectors.

Corporate Governance

Related Party Transactions

• The acquisition of shares by a director from the company through an equity incentive program constitutes a related party transaction, as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: Increased director ownership can be viewed positively as it aligns the director's financial interests with shareholder value creation.

Key Dates

Keywords

Amgen, AMGN, SEC Form 4, Insider Transaction, Director Stock Ownership, Restricted Stock Units, Equity Incentive Plan, Biotechnology, Pharmaceuticals